Payment overview · 2025
General Payments
$1,183.36
41 reported records · 8 companies
Healthcare provider profile · identity verified
Fnu Mohammed Faizullah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1831615194
Verified facts
What the public records show
CMS Open Payments records show Fnu Mohammed Faizullah, MD received $1,183.36 in general payments during 2025 across 41 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $578.75 | 48.9% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $227.16 | 19.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.54 | 12.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $89.72 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.68 | 4.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.93 | 3.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.04 | 2.9% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $16.54 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,183.36 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $578.75 | 23 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $227.16 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $206.58 | 9 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $149.54 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $89.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| Gamifant Normalized: gamifant |
Drug | SOBI, INC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 340 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
340 | 66 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
97 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1154 | 311 |
| Amlodipine Besylate | Amlodipine Besylate | 696 | 195 |
| Losartan Potassium | Losartan Potassium | 662 | 183 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 593 | 118 |
| Metformin Hcl | Metformin Hcl | 578 | 152 |
| Diclofenac Sodium Er | Diclofenac Sodium | 454 | 31 |
| Nifedipine Er | Nifedipine | 415 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 414 | 105 |
| Januvia | Sitagliptin Phosphate | 382 | 66 |
| Gabapentin | Gabapentin | 362 | 96 |
| Farxiga | Dapagliflozin Propanediol | 340 | 66 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 295 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 65 |
| Eliquis | Apixaban | 206 | 42 |
| Furosemide | Furosemide | 197 | 51 |
| Ammonium Lactate | Ammonium Lactate | 193 | 49 |
| Enalapril Maleate | Enalapril Maleate | 187 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 183 | 75 |
| Carvedilol | Carvedilol | 180 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 48 |
| Omeprazole | Omeprazole | 155 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 39 |
| Famotidine | Famotidine | 141 | 47 |
| Lisinopril | Lisinopril | 141 | 38 |
| Montelukast Sodium | Montelukast Sodium | 141 | 34 |
| Doxepin Hcl | Doxepin Hcl | 140 | suppressed |
| Simvastatin | Simvastatin | 132 | 33 |
| Memantine Hcl | Memantine Hcl | 130 | 25 |
| Finasteride | Finasteride | 125 | 32 |
| Ozempic | Semaglutide | 122 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 33 |
| Trulicity | Dulaglutide | 120 | 17 |
| Xarelto | Rivaroxaban | 120 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 34 |
| Spironolactone | Spironolactone | 107 | 24 |
| Chlorthalidone | Chlorthalidone | 104 | 30 |
| Kerendia | Finerenone | 97 | 31 |
| Entresto | Sacubitril/Valsartan | 93 | 19 |
| Glimepiride | Glimepiride | 92 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 20 |
| Jardiance | Empagliflozin | 87 | 21 |
| Meclizine Hcl | Meclizine Hcl | 85 | 20 |
| Latanoprost | Latanoprost | 84 | 30 |
| Tradjenta | Linagliptin | 83 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 80 | 18 |
| Lactulose | Lactulose | 80 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 78 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 20 |
| Levetiracetam | Levetiracetam | 67 | 18 |
| Alendronate Sodium | Alendronate Sodium | 66 | 17 |
| Ezetimibe | Ezetimibe | 66 | 19 |
| Metformin Hcl Er | Metformin Hcl | 66 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 61 | suppressed |
| Valsartan | Valsartan | 61 | 14 |
| Single Use Swab | Alcohol Antiseptic Pads | 60 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 17 |
| Glipizide Er | Glipizide | 57 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 12 |
| Brilinta | Ticagrelor | 54 | 11 |
| Glipizide | Glipizide | 53 | 13 |
| Naproxen Sodium | Naproxen Sodium | 53 | 17 |
| Rybelsus | Semaglutide | 50 | 11 |
| Allopurinol | Allopurinol | 46 | 12 |
| Azelastine Hcl | Azelastine Hcl | 46 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Clotrimazole | Clotrimazole | 46 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 45 | suppressed |
| Cilostazol | Cilostazol | 44 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 16 |
| Etodolac | Etodolac | 42 | 20 |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Calcitriol | Calcitriol | 40 | 13 |
| Myrbetriq | Mirabegron | 39 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 14 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Folic Acid | Folic Acid | 37 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 32 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 31 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 29 | suppressed |
| Fluocinonide | Fluocinonide | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Prednisone | Prednisone | 22 | 12 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Naproxen | Naproxen | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,183.36 · 41 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, CeQur Simplicity, DALVANCE, FARXIGA, GVOKE HYPOPEN, Gamifant, Kerendia, Ozempic, Rybelsus | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error